These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9219265)

  • 1. Increasing the serum persistence of an IgG fragment by random mutagenesis.
    Ghetie V; Popov S; Borvak J; Radu C; Matesoi D; Medesan C; Ober RJ; Ward ES
    Nat Biotechnol; 1997 Jul; 15(7):637-40. PubMed ID: 9219265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice.
    Ghetie V; Hubbard JG; Kim JK; Tsen MF; Lee Y; Ward ES
    Eur J Immunol; 1996 Mar; 26(3):690-6. PubMed ID: 8605939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1.
    Medesan C; Matesoi D; Radu C; Ghetie V; Ward ES
    J Immunol; 1997 Mar; 158(5):2211-7. PubMed ID: 9036967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor.
    Kim JK; Tsen MF; Ghetie V; Ward ES
    Eur J Immunol; 1994 Oct; 24(10):2429-34. PubMed ID: 7925571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
    Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
    Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FcRn mediates elongated serum half-life of human IgG in cattle.
    Kacskovics I; Kis Z; Mayer B; West AP; Tiangco NE; Tilahun M; Cervenak L; Bjorkman PJ; Goldsby RA; Szenci O; Hammarström L
    Int Immunol; 2006 Apr; 18(4):525-36. PubMed ID: 16481343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
    Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
    J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced elimination of IgG antibodies by engineering the variable region.
    Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
    Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
    Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
    Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
    Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
    Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
    Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
    Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MHC class I-related FcRn ameliorates murine Lyme arthritis.
    Crowley H; Alroy J; Sproule TJ; Roopenian D; Huber BT
    Int Immunol; 2006 Mar; 18(3):409-14. PubMed ID: 16415101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin.
    Andersen JT; Dee Qian J; Sandlie I
    Eur J Immunol; 2006 Nov; 36(11):3044-51. PubMed ID: 17048273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albumin binding to FcRn: distinct from the FcRn-IgG interaction.
    Chaudhury C; Brooks CL; Carter DC; Robinson JM; Anderson CL
    Biochemistry; 2006 Apr; 45(15):4983-90. PubMed ID: 16605266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid IgA2/IgG1 antibodies with tailor-made effector functions.
    Chintalacharuvu KR; Vuong LU; Loi LA; Larrick JW; Morrison SL
    Clin Immunol; 2001 Oct; 101(1):21-31. PubMed ID: 11580223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative methods for developing Fc mutants with extended half-lives.
    Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
    Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice.
    Israel EJ; Patel VK; Taylor SF; Marshak-Rothstein A; Simister NE
    J Immunol; 1995 Jun; 154(12):6246-51. PubMed ID: 7759862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.